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Abstract
Lupus nephritis (LN) occurs between 30% and 70% of patients with systemic lupus erythematosus (SLE), 
depending on race and sex. LN appears early in the disease with prevalence of severe forms such as classes 
III, IV and mixed (V + III IV or V +). 50% of adults and 70% of children with lupus born in Colombia, 
suffer LN sometime in their lifetime; in this population 25% of children and 38% of adults have nephrotic 
syndrome. The remission rate at six months is low, the proteinuria in nephrotic range, and the incraease of 
baseline creatinine predict failure to achieve remission at 6 months.
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Nefropatía lúpica
Resumen
La nefritis lúpica (NL) se presenta entre el 30 y 70% de los pacientes con lupus eritematoso sistémico 
(LES), dependiendo de la raza y el sexo, ocurre temprano en la enfermedad y predominan las formas gra-
ves, clases III, IV y mixtas (V + III o V + IV). El 50% de los adultos y 70% de los niños colombianos con 
lupus sufren NL en algún momento de la vida; en esta población el 25% de los niños y el 38% de los adultos 
presentan síndrome nefrótico, la tasa de remisión a 6 meses es baja, la proteinuria en rango nefrótico y la 
elevación de creatinina basal, predicen falla en el logro de remisión a 6 meses.
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Introduction
Lupus nephritis (LN) is defined, according to ACR (American College of Rheumatology)1, its LN2 guidelines and recommendations EULAR / ERA-EDTA (European League Against Rheumatism and European Renal Association-European Dyalisis and Trasplant Association)3, such as the pre-
sence of persistent proteinuria> 500 mg / 24 hours, or 3+ count in occasional urine sample, or the presence 
of cell cylinders (haematocytic, granular, tubular or mixed). The SLICC group (Systemic Lupus Erythe-
matosus International Collaboration Clinics) 4 defines it by the presence of proteinuria ≥500 mg / 24 hours 
or proteinuria / creatinuria (UPCR) ≥50 mg / mmol or erythrocyte cylinders. It states that the presence 
of renal biopsy compatible with LN plus the presence of antinuclear antibodies (ANA) or antiDNA, are 
sufficient criteria to classify as a lupus patient.
http//doi.org/10.22265/acnef.1.2.182
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The frequency of LN varies according to race, sex 
and age; in the EUROLUPUS5 cohort, with 1,000 
patients, 97% of them caucasian, 16% had LN at 
the beggining of the disease and 36% during their 
evolution. Overall, 30% of the patients with LN are 
white6 and 60% are African-American7. In the GLA-
DEL8 cohort (Latin American Lupus Study Group, 
with the acronym in english), 51.7% of the patients 
presented LN, 58.3% were mestizos and Afro-Latin 
Americans and 43.6% were white Latin-Americans. 
Similar proportions are described in the LUMINA9 
cohort (Lupus in Minories Nature or Nurture). In 
Colombia 50% to 55% of adults10-12 and 75% of 
children13 with systemic lupus erythematosus (SLE) 
suffer LN at some point in their evolution.
Between 10% and 25% of adults with LN will pro-
gress to end-stage cronic kidney disease (CKD) 14,15. 
The proliferative forms are the most serious, com-
mon and those that most lead to IRCT16.
In Colombia, there are no prospective studies that 
determine the percentage of patients with LN who 
will later develop ESRD, but in several cohorts se-
vere histological forms predominate10,11,17. Using 
the histological classification of the World Health 
Organization (WHO), in 2 cohorts located at the city 
of Medellín, a predominance of proliferative forms 
was found. In a population of 46 patients with LN 
in the Hospital Universitario San Vicente de Paul11, 
46% had LN class IV, 7.8% class III, 9.3% mixed 
forms (membranoproliferative) and 15.6% class V 
(pure membranous). In a group of 32 patients with 
LN at Clinica Leon XIII10, LN class IV represented 
50%, Class III 10%, and Class V 19% of the biopsies 
performed.
According to the classification of the International 
Society of Nephrology and the Society of Renal Pa-
thology, ISN / RPS, in 140 biopsies performed at the 
Pablo Tobón Uribe Hospital, we found that 83.87% 
of cases had proliferative LN (Class IV 63.75 %, 
Class III 13.42% and mixed forms, V / III or V / IV, 
6.7%)18; Likewise, in a population selected for seve-
rity and resistance to standard immunosuppression, 
treated with rituximab (RTX), 76% of the patients 
had proliferative LN19.
SLE appears to be more severe in children and tee-
nagers; Between 60% and 80% present LN during 
their evolution, two thirds with histological classes 
III or IV. Between 10% and 50% reach IRCT20,21.
Pathological anatomy
Renal biopsy is of great importance in the diagnostic 
approach of NL16; the clinical-pathological correla-
tion is inaccurate11, so the result of the renal biopsy 
is a guidance tool to determine the treatment and to 
provide information about the prognosis3,22,23. Ad-
ditional, it will rule out antiphospholipid syndrome 
(APS) nephropathy24,25, thrombotic microangiopa-
thy26  and primary glomerulopathy.
The instruction to perform renal biopsy vary accor-
ding to the working groups; ACR2 indicates renal 
biopsy in patients with SLE who show increased 
creatinine without alternative causes such as sepsis, 
hypovolemia or medications; confirmed proteinuria 
≥1 gram / 24 hours; or the combination of proteinu-
ria ≥500 mg / 24 hours and cell cylinders; or hematu-
ria ≥ 5 AP erythrocytes. The EULAR / ERA-EDTA3 
guidelines suggest renal biopsy in all lupus patients 
with reproducible proteinuria ≥ 500 mg / 24 hours, 
especially if they have glomerular hematuria or ce-
llular cylinders.
The consensus of the group of systemic autoimmune 
diseases (GEAS) of the Spanish Society of Nephro-
logy (SEN) and the Spanish Society of Internal Me-
dicine (SEMI) 23 indicate the renal biopsy in all 
patients with SLE that present: unexplained deterio-
ration of renal function; Proteinuria confirmed ≥500 
mg / 24 hours; UPCR ≥50 mg / mmol in morning 
sample or in 24-hour period urine; or active urinary 
sediment. All 3 groups suggest using the ISN / RPS 
classification of 200327 (Table 1).
The ISN / RPS classification seeks to unify concepts 
and homogenize terms by modifying the WHO clas-
sification28,29. According to this new classification27, 
subendothelial or subepithelial deposits may be de-
monstrated by electron microscopy or immunofluo-
rescence but not by light microscopy in Class II. 
Class III and Class IV are subdivided into active (A), 
chronic (C) and active-chronic (A / C), depending on 
the characteristics of the histological lesions. In turn, 
the LN Class IV is subdivided into global (≥50% 
of the glomeruli involved have global lesions) and 
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segmental (≥50% of the involved glomeruli have 
segmental lesions). The ISN / RPS work group pro-
poses that all renal biopsies are evaluated by light 
microscopy (hematoxylin & eosin, silver - methena-
mine, PAS and trichrome), of immunofluorescence 
(IgG, IgA, IgM, C3, C1q, kappa and Lambda) and 
electrons.
All LN classifications emphasize in glomerular and 
vascular findings, which should always be comple-
mented with activity indexes (AI) and chronicity 
(CI). This indexes will include significant tubuloin-
terstitial findings (valuable for the prognosis), and 
give semiquantitative information of the pathologi-
cal renal anatomy30.
Although the ISN / RPS classification is used by the 
vast majority of the groups, there are several criti-
cal aspects to this: the prognostic studies were made 
based on the WHO classification; the presence of a 
single glomerulus with active or chronic lesions is 
enough to classify proliferative lesions as A or C31; 
the differentiation between global and segmental 
forms is not always easy and is of great importan-
ce in the pathophysiology and prognosis of LN; and 
does not include tubular lesions or arteriolar invol-
vement.
Overall, histological classes I and II have an indo-
lent course and III and IV, without treatment, pre-
sent progressive renal damage32. However, histo-
logical transformation is frequent27; 66% of Class 
III LN patients and 18% Class V LN patients are 
spontaneously reclassified to class IV or to less se-
vere classes with immunosuppressive therapy. The 
probability of doubling the creatinine, reach ESRD, 
or dye is higher in proliferative forms (32% class IV, 
30% class III, 18% class V, 5% class II, p <0.025) 
and in those with high activity indexes (AI 7 ± 6 
vs. 5 ± 5, p <0.05) and chronicity indexes (CI 4 ± 3 
vs. 2 ± 2). Patients with extracapillary proliferation 
(crescentic GN)  in the cell phase and interstitial fi-
brosis are considered to be at high risk for ESRD 
(70% at 90 months, p <0.0001 vs. patients without 
these findings) 34. No study evaluates the differences 
in the prognosis of patients with LN Class II with or 
without subepithelial or subendothelial deposits. 
A very important aspect to evaluate the prognosis 
and define the treatment of patients with LN is the 
coexistence of nephropathy due to APS. The charac-
teristic lesions are MAT (acute lesions) and fibrous 
intimal hyperplasia (chronic vascular lesions). It 
also includes atherosclerosis, organized thrombosis 
and ischemic subscapular focal cortical atrophy35,36. 
In a French cohort, 32% of the patients with LN 
had overlapping, histological findings suggestive of 
APS nephropathy, without systemic manifestations 
of APS in 22% of the cases. The noted histological 
findings were associated with systemic APS, lupus 
anticoagulant, hypertension, interstitial fibrosis and 
elevated creatinine. In a Colombian cohort of pa-
tients with APS37, 16% of patients had some type of 
nephropathy (LN 11%, MAT 1% and diffuse prolife-
rative glomerulonephritis with full house pattern and 
serology for persistently negative SLE 1%)38.
Patients with SLE may present VT in the context of 
a thrombotic thrombocytopenic purpura39 or have it 
only at the renal level, which may be present in up 
to 8.3% of the biopsies40. Patients with renal matu-
ration present more severe clinical manifestations41, 
Table 1. HisTological classificaTion of lupus 
nepHropaTHy according To THe inTernaTional socieTy 
of nepHrology and THe socieTy of renal paTHology 
2003
Class I: Minimal mesangial nephritis
Normal light microscopy with mesangial deposits in 
immunohistology and electron microscopy
Class II: Proliferative mesangial nephritis
Broadening and / or mesangial proliferation in light microscopy
Class III: Focal proliferative nephritis (A, A / C, C)
Intracapillary proliferation in less than 50% of the glomeruli, 
with subendothelial immune deposits
Class IV: Diffuse proliferative nephritis (A, A / C, C)
Intracapillary proliferation in 50% or more of the glomeruli, with 
subendothelial immune deposits
Case V: Membranous nephritis
Subepithelial immune deposits; Classes II, III or IV may coexist
Class VI: Advanced sclerosing nephritis
Global sclerosis in more than 90% of the glomeruli
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with more proteinuria, greater frequency of renal 
failure, hypertension and malignant hypertension, 
and worse prognosis in the short and long term with 
an increased risk of ESRD and death. Only 60.6% 
of them had microangiopathic hemolytic anemia41 
so presence of thrombi in the glomeruli should be 
sought in all cases.
Special subgroups
Three additional aspects of histopathology should 
be analyzed when reviewing the renal biopsy of pa-
tients with SLE: Pauciinmune glomerulonephritis, 
focal and segmental, crescentic glomerulonephritis 
and vascular lesions.
In the focal and segmental LN, only a portion of 
the glomeruli and glomerular plume are affected, 
while the others are not affected; Immune deposits 
are often absent from focal lesions resembling the 
pauciimmunes found in ANCA-associated vasculi-
tis41-43. Some authors find that patients classified by 
WHO as class III but with severe segmental affec-
tion (≥50% of the glomeruli) have a worse prognosis 
than patients with LN class IV44-45. By definition of 
the ISN / RPS classification, these patients could be 
classified as IV-G being in fact extensive segmental 
forms, with different pathophysiology and progno-
sis. Schwartz et al., 43 evaluated 83 renal biopsies 
with severe forms of LN that had proliferation or 
necrosis in ≥50% of the non-sclerotic glomeruli and 
classified by WHO as: severe segmental (class III 
with affection ≥50% of the glomeruli), global diffu-
se (class IV) and membranous (V ± III and V ± IV). 
These biopsies were recategorized to the ISN / RPS 
terminology and they found that 26.5% of the cases 
had segmental affection that compromised > 50% of 
the glomerular plume in ≥50% of the glomeruli. Al-
though they had affection of more than 50% of the 
glomerular plume, in fact these patients had extensi-
ve, non-global segmental forms. The importance of 
this is that this subgroup of patients had a lower rate 
of remission, renal survival, stability of renal func-
tion and higher rates of ESRD and mortality than 
IV-G and IV-S glomerulonephritis. There are histo-
logical differences that could explain these findings; 
The biopsies performed with severe segmental glo-
merulonephritis have fewer subendothelial immune 
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deposits, hyaline thrombi and wire loops than glo-
bal proliferative glomerulonephritis. This menaning 
they are more pauciimmune, however, they have 
more damage to the capillary wall44.
Patients with rapidly progressive glomerulonephritis 
(RPGN) represent a separate subgroup; They typica-
lly have accelerated renal failure with loss of renal 
function in ≤3 months, evidence of glomerular in-
jury with active urinary sediment and extracapillar 
proliferation46. Characterization of these biopsies by 
immunohistology shows 3 patterns: Type 1: granular 
pattern, characteristic of immune complex glomeru-
lopathies, Type 2: linear pattern, basal glomerular 
antimembrane and Type 3: pauciinmune, observed 
in vasculitis associated with ANCA and glomerulo-
nephritis Crescéntica pauciinmune.
Being SLE a disease with high humoral immunity, 
RPGN patients would be expected to have Type 1. 
However, severe forms of RPGN are described with 
prominent fibrinoid necrosis and extracapillary pro-
liferation with minimal or absent subendothelial im-
mune deposits and positive ANCA47,48. Crescentic 
glomerulonephritis is not uncommon in lupus. It is 
observed in 10% of all renal biopsies and in 21.7% 
of LN IV-G49; ANCA may play a pathogenic role 
in crescentic nephritis and segmental necrosis45-50. 
Patients with crescentic forms are less likely to have 
partial or complete remission and an increased risk 
of relapse, double creatinine values, have ANCA po-
sitive, and RD (IRCT en español). They present with 
more inflammation and interstitial fibrosis, tubular 
atrophy and indexes of activity and chronicity47.
Another important aspect for the prognosis of LN 
is non-glomerular vascular compromise. Appel and 
et al., 51 described, for the first time, the term lu-
pus vasculopathy as a non-inflammatory renal ne-
crotizing microangiopathy, without thrombi and no 
association with APS. In a study of 169 renal biop-
sies of French patients with LN52, arteriolesclerosis 
(49.7%), vascular wall (30.2%), lupus vasculopathy 
(24.3%), vasculitis (2.4%) and MAT (0.6%) were 
found. Patients with vascular involvement had a hi-
gher percentage of LN IV WHO, more hypertension, 
anemia, renal failure, proteinuria, nephrotic syndro-
me, hypocomplementemia, and thrombocytopenia 
than those without vascular affection. In Chinese 
patients, 43,53 the distribution of forms of vascular 
disease was different: 66% had vascular immune 
deposits, 12.6% arteriolesclerosis, 12% MAT, 6.3% 
non-inflammatory necrotizing vasculopathy, 1.4% 
vasculitis and 28% more than 2 forms of vascular 
injury. Patients with lupus vasculopathy presented 
more severe histological pictures, major AI and 
CI, endocapillary hypercellularity, karyorrhexis, fi-
brinoid necrosis, subendothelial deposits, tubular 
atrophy and interstitial fibrosis. They also presented 
more hematological cytopathies, hypocomplemen-
temia and retention of sweat.
In patients with proteinuria of low magnitude, as in 
all other cases, the clinical - pathological correlation 
is inaccurate and may be severe LN in the initial 
phases. In the John Hopkins cohort55 evaluated the 
findings of 21 kidney biopsies made while patients 
had proteinuria <1 gram / 24 hours or UPCR <1. In 
this group, which represented 6.4% of the sample, 
they found 5 cases of LN class III, one class IV, one 
class V and 6 class V associated to III or IV. One 
biopsy showed MAT. The only difference between 
patients with severe and mild histological forms was 
hypocomplementemia in the former. Therefore, pa-
tients with SLE with mild protenuria, clean sediment 
and normal renal function may have severe histolo-
gical forms. C3 hypocomplementemia could suggest 
the presence of proliferative glomerulonephritis in 
this subgroup56.
Clinical Manifestations and Predictors of 
Remission
LN is manifested in 6 different clinical-pathologi-
cal patterns: dominant proteinuria with or without 
telescoped sediment, acute or chronic renal failure, 
nephritic syndrome with or without renal failure, 
RPGN, nephrotic syndrome and aggregated MAT16. 
In our setting LN is presented early in the natural 
history of the disease. In a cohort of 56 Colombian 
children, 16.1% had nephrotic syndrome and 14.3% 
nephrotic syndrome at diagnosis of SLE. In a popu-
lation of 104 Colombian adults with SLE10, 35.7% 
had nephritis on diagnosis. In a cohort of 84 patients 
from the city of Medellín17, we observed that LN 
was present on an average of 13.6 (0 - 168) months 
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after diagnosis of SLE. The diagnosis of SLE and 
LN agreed in 36.9% of the patients. 63% of those 
who had LN presented it within the first 6 months 
and 72% during the first year. 
The frequency of nephrotic syndrome varies among 
different ethnic groups. In the Colombian series 
analyzed, 25% of children13 and up to 38% of 
adults10,11,17 progress as stated. In the GLADEL8 
cohort, 5.7% of whites, 6.7% of mestizos and 10.5% 
of Afro-Latin Americans with SLE had nephrotic sy-
ndrome. This manifestation is more frequent in Afri-
can American lupus patients6 and less frequent in 
caucasians57. In our study, 40% of patients with LN 
III, 41% of LN IV, 50% of mixed forms and 70% of 
LN V, had proteinuria in the nephrotic range11.
A very important aspect in the initial approach of 
patients with LN is to detect response predictors to 
the treatment, doubling of creatinine, ESRD and 
death. Baseline levels of creatinine and proteinuria, 
HT, anti-DNA antibodies, C3 and C4 hypocomple-
mentemia, high AI and CI, and race are poor factors 
prognosis in patients with proliferative LN16,32,58-
65. Failure to achieve partial (PR) or complete re-
mission (RC) at 6 months is associated with poor 
prognosis in the long term and implies greater use of 
immunosuppressants16. In Asian patients the longer 
time to achieve remission and failure to achieve CR 
are relapse predictors and ESRD. On the other hand, 
normalization of creatinine in the first 48 weeks67, 
proteinuria in the first 5268 weeks and the decrease 
of this to less than 1 gram / 24 hours in the first 2469 
weeks, were good predictors of prognosis in Cauca-
sian patients with LN.
In a cohort of Colombian patients with proliferati-
ve LN treated with steroids and cyclophosphami-
de (CP) or mycophenolate mofetil (MPM) 17 only 
44% achieved PR or CR at 6 months (23.8% CR and 
20.2% PR); 52.7% of the women and 80% of the 
men failed to achieve PR or CR at 6 months. The 
23.4% of those who failed, reached at least PR at 
12 months. In the multivariate analysis, the baseline 
alteration of renal function (OR 10.92, 95% CI 2.65 
- 45.02, p = 0.001) and proteinuria in the nephro-
tic range (OR 9.81, 95% CI 1.85-54-04, p = 0.007) 
were Independent predictors of failure to achieve PR 
or CR at 6 months.
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Treatment
The purpose of treatment of LN are: complete remi-
sion CR, or at least partial remision PR, at 6 mon-
ths and not after 12 months; avoid irreversible renal 
damage, dialysis, transplantation and death, always 
looking for the lowest possible toxicity by medica-
tions; and preserving the quality of life3.
The studies that evaluate the CR and PR outcomes 
are very heterogeneous by different definitions of 
response. The ACR defines CR as a glomerular fil-
tration rate (GFR)> 90 mL / min / 1.73 m2 body 
surface area, proteinuria <500 mg / 24 hours (or 
UPCR <50 mg / mmol) and clean urinary sediment 
(<5 erythrocytes or leukocytes AP) 70. The EULAR 
/ ERA-EDTA guidelines propose similar CR and PR 
criteria but define renal function response as normal 
or "almost normal" (maximum GFR 10% below 
normal) 3.
The current immunosuppression regimens consist of 
an induction phase and a maintenance phase2,3. In-
duction therapy is done with steroids in combination 
with immunosuppressants, MMP or CPM. The su-
ggested steroid regimen is intravenous methylpred-
nisolone 500 mg / day administered in 3 doses (1 
gram if extracapillary proliferation is demonstrated) 
followed by prednisolone 0.5-1 mg / kg / day in de-
creasing doses. If MMP is chosen the recommended 
dose is 2 - 3 grams / day. If CPM is chosen, there 
are 2 forms of administration: 0.75 - 1 gram / m2 / 
month for 6 months (National Institutes of Health, 
NIH) 71  or 750 mg, fixed dose, every 15 days for 
6 doses EUROLUPUS scheme ") 57. The EULAR 
/ ERA-EDTA3 guidelines only recommend the se-
cond scheme.
The classic studies of NIH72,73  left us several les-
sons: in the treatment of LN steroids alone are infe-
rior to their combination with cytotoxic; azathioprine 
(AZA) is inferior to CPM in induction of remission; 
short schemes (6 months) with CPM are long-term 
inferior to long-term (24-month) schedules; CPM 
in monthly or quarterly pulses confers less toxici-
ty than daily oral administration and methylpredni-
solone pulses aid in subsequent use of lower doses 
of steroids. The use of CPM for periods of 2 years 
was associated with an increased risk of premature 
ovarian failure, leukopenia, infections and dysplasia 
of the cervix72. As an alternative with less toxicity, 
the EUROLUPUS study showed similar results al-
though the benchmark was not the NIH scheme and 
included only Caucasian patients57,69,74.
The controlled clinical studies (RCTs) that buy 
MMP and CPM in induction of proliferative LN 
remission71, 74-78 have been tested in 2 recent me-
ta-analyzes79,80 that showed no difference in the 
achievement of PR, CR and stabilization of renal 
function. CPM causes more alopecia and ovarian 
failure and MMP more diarrhea, but there were no 
differences in the presence of herpes zoster and ma-
jor infections and the risk of ESRD.  Death was the 
same for both drugs.
In the choice between CPM and MMP factors such 
as age21, race75, reproductive future and severity of 
the clinical presentation. While most clinicians pre-
fer CPM for severe cases, successful stories of proli-
ferative LN treatment with impaired renal function, 
vasculopathy, and crescentic glomerulonephritis has 
recently been reported with MMP81-83. Mycopheno-
late sodium80 and tacrolimus84 have also been tes-
ted for induction of remission on proliferative LN 
with favorable results.
According to the recommendations of EULAR and 
ACR, patients who have not achieved PR or CR at 6 
months should be reintroduced with methylpredni-
solone followed by a full dose of prednisolone com-
bined with CPM or MMP (which was not chosen in 
the initial treatment). When there is failure to rein-
duction, treatment with RTX or cyclosporin A (CsA) 
is suggested.
Patients who reach PR or CR go to maintenance pha-
se with MMF (1 - 2 g / day) or AZA (2 mg / kg / day). 
The therapy used to keep up the treatment should be 
continued for at least 3 years to avoid relapse2,3,85. 
Studies comparing MMP and AZA in maintenance 
therapy86,89, grouped in a recent meta-analysis90, 
showed no difference in relapse rates, IRCT, and 
death. Patients treated with AZA had more leukope-
nia and amenorrhea but there was no difference in 
adverse gastrointestinal events nor infections. The 
extension of the study ASPREVA87 favors MMP and 
the study MAINTAIN88 to AZA.
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Rituximab, in the induction of proliferative LN re-
mission has only been evaluated in a randomized 
controlled trial (RCT) 91 that did not demonstrate 
that it was better than the use of placebo in reaching 
a partial or complete response in patients receiving 
steroids and MMF. Patients in the RTX group had 
a greater decrease ≥ 50% in proteinuria (p = 0.04), 
required fewer CPM rescues (p = 0.006) and reached 
greater steroid savings, anti-DNA antibody titers, 
and normalization of C3 levels. 
"Real-life" studies92-100, mostly cohorts, show di-
fferent results than the LUNAR study. Most of the 
patients received RTX due to failure to manage im-
munosuppressors, some in combination with MMP 
or CPM and others as monotherapy. The main con-
clusion of these studies is that RTX would be ac-
curate in refractory cases of proliferative LN. This 
is the indication of the recommendations given by 
ACR and EULAR / ERA-EDTA. In patients from 
Colombia19, 75% of them with refractory LN to two 
or more immunosuppressants, a significant impro-
vement of proteinuria, creatinine clearance, lupus 
activity measured by SELENA-SLEDAI and a de-
crease in steroid requirements were observed. After 
12 months of treatment with RTX, 61.5% of the pa-
tients achieved PR or CR by the parameter proteinu-
ria, and 33% by the parameter creatinine clearance. 
20% of the patients required RTX retreatment, on 
average at 44 months (95% CI 10.1 - 50.1).
For patients with refractory LN (NB?)and associa-
ted VTE, plasma spares have been used and in cases 
of active LN and aggregated infection, intravenous 
gammaglobulin. None of these treatments has been 
tested in RCT, only in open studies80.
The membranous glomerulonephritis with class III 
or IV associated, are treated as proliferative LN. The 
pure V forms represent between 0% and 19% of the 
cases published in Colombia10-13. The ACR2 and 
EULAR / ERA-EDTA3 guidelines recommend ini-
tiating with prednisolone 0.5 mg / kg / day and MMF 
or AZA. If there is no favorable response at 6 mon-
ths they suggest the use of CFM and methylpredni-
solone pulses. For refractory cases there is evidence 
of a favorable effect with CsA101 and RTX93,94.
Coadjuvant therapies are vital in the prognosis of 
LN. All patients with proteinuria ≥ 500 mg / 24 
hours should receive inhibitors of the angiotensin 
converting enzyme or angiotensin receptor blockers. 
These drugs reduce up to 30% proteinuria values 
and delay the duplication of creatinine and CRIT in 
non-diabetic patients2,3. Blood pressure targets ≤130 
/ 80 and strict control of dyslipidemia are indicated. 
Hydroxychloroquine decreases the damage accu-
mulated including in renal function and relapses. It 
should be received by all patients with SLE and LN, 
excluding those with contraindications102,103.
Collaborations
Adriana Flórez Vargas, Nephropathologist, Fun-
dación Santa Fe de Bogotá and Mauricio Lopera, 
Nephrologist RTS - Baxter Medellín, by histopatho-
logical images.
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